Business
BioRestorative Therapies Announces Notices of Allowance for Three Patent Applications for its Off-the-Shelf ThermoStem® Program
MELVILLE, N.Y., March 22, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company”) (OTC: BRTX), a life sciences company focused on stem
About this update from Biorestorative Therapies, Inc.
[{"type":"text","content":"MELVILLE, N.Y., March 22, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company”) (OTC: BRTX), a life sciences company focused on stem cell-based therapies, today announced that the United States Patent Office and several International agencies have issued notices of allowance for three separate patent applications related to the Company’s metabolic ThermoStem® Program. The notices of allowance were for a total of three patent applications and covered the United States, Israel, France, Germany, Italy, Spain, and the United Kingdom. The applications have issued or are expected to issue as patents in 2021. These patent allowances will allow for the protection of a specific isolated human brown adipose tissue-derived stem cell capable of differentiating into multiple cell types and their applications. This particular cell possesses strong characteristics applicable for potential therapeutic uses for treating a wide range of degenerative and metabolic disorders with billion-dollar market opportunities. “Our ThermoStem® Program is a platform technology that we expect will create a valuable therapeutic pipeline for BioRestorative. These patent application notices of allowance further strengthen our position as a leader in the development of brown adipose therapeutics,” said Francisco Silva, the Company’s Vice President of Research and Development. “Adding intellectual property to this family of patents will protect us as we seek to expand our off-the-shelf clinical development programs.” Lance Alstodt, President and CEO of the Company, added, “I am very impressed with the rate and significance of the advancement of our intellectual property, further strengthening our fundamental value inherent in the technology. We continue to follow a strict protocol for achieving our strategic goals that were outlined earlier this year and look forward to transitioning our off-the-shelf cell therapy to the clinic.” About BioRestorative Therapies, Inc. BioRestorative Therapies, Inc. (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. Our two core programs, as described below, relate to the treatment of disc/spine disease and metabolic disorders: • Disc/Spine Program (brtxDISC™): Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous (...